Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
27.04 USD | +1.79% | -1.71% | -6.57% |
05-23 | Supernus Pharmaceuticals Reports 'Clinical Utility' From Epilepsy Treatment Study | MT |
05-23 | Transcript : Supernus Pharmaceuticals, Inc. - Special Call |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-6.57% | 1.46B | |
+15.54% | 77.63B | |
+12.05% | 8.78B | |
+58.17% | 4.93B | |
-14.94% | 4.79B | |
0.00% | 3.8B | |
+21.94% | 2.46B | |
-26.63% | 2.2B | |
+16.75% | 2.1B | |
-37.97% | 1.96B |
- Stock Market
- Equities
- SUPN Stock
- News Supernus Pharmaceuticals, Inc.
- Earnings Flash (SUPN) SUPERNUS PHARMACEUTICALS Reports Q1 Revenue $143.6M, vs. Street Est of $145.8M